These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 35752951)

  • 1. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
    Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
    Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
    Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.
    Wright BJ; Tideman S; Diaz GA; French T; Parsons GT; Robicsek A
    Lancet Respir Med; 2022 Jun; 10(6):557-565. PubMed ID: 35227415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
    Tang F; Hammel IS; Andrew MK; Ruiz JG
    Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
    Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
    BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Bejko D; Ernst C; Vergison A; Stranges S; Zeegers MP; Mossong J
    Vaccine; 2024 Sep; 42(22):126011. PubMed ID: 38825555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
    McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
    Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of COVID-19 vaccine effectiveness against infections and severe outcomes using routine surveillance data in Kosovo, July-September 2021.
    Rashiti-Bytyçi A; White Johansson E; Kaçaniku-Gunga P; Danis K; Schoeps A; Dörre A; Fetaj F; Kalaveshi A
    PLoS One; 2024; 19(7):e0305629. PubMed ID: 39046982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study.
    Homan T; Mazzilli S; Chieti A; Musa A; Roth A; Fortunato F; Bisceglia L; Prato R; Lopalco PL; Martinelli D
    Sci Rep; 2022 Nov; 12(1):18597. PubMed ID: 36329239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
    Rosero-Bixby L
    JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Liu B; Gidding H; Stepien S; Cretikos M; Macartney K
    Vaccine; 2022 Oct; 40(43):6288-6294. PubMed ID: 36180375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.